List of Lonsurf drug patents

Lonsurf is owned by Taiho Oncology.

Lonsurf contains Tipiracil Hydrochloride; Trifluridine.

Lonsurf has a total of 5 drug patents out of which 0 drug patents have expired.

Lonsurf was authorised for market use on 22 September, 2015.

Lonsurf is available in tablet;oral dosage forms.

Lonsurf can be used as method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf, treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy.

The generics of Lonsurf are possible to be released after 03 February, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9527833 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

US10457666 TAIHO ONCOLOGY Stable crystal form of tipiracil hydrochloride and crystallization method for the same
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46284 TAIHO ONCOLOGY Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
Sep, 2029

(6 years from now)

US10456399 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(14 years from now)

US10960004 TAIHO ONCOLOGY Method for treating cancer patients with severe renal impairment
Feb, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Feb 22, 2022
Orphan Drug Exclusivity (ODE) Feb 22, 2026

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Market Authorisation Date: 22 September, 2015

Treatment: Treatment of adults with metastatic gastric or gja previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropiate, her2/neu-targeted therapy; Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy; Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf

Dosage: TABLET;ORAL

How can I launch a generic of LONSURF before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic